<DOC>
	<DOCNO>NCT01639573</DOCNO>
	<brief_summary>This phase I/II pilot trial seek demonstrate prolong administration Campath-1H without prior marrow stem cell harvest result immunoablation similar achieve hematopoietic stem cell transplantation ( HSCT ) either bone marrow peripheral blood stem cell source child adolescent severe treatment refractory systemic sclerosis ( SSc ) .</brief_summary>
	<brief_title>Campath-1h Phase I/II Pilot Trial Immunoablative Therapy Refractory Systemic Sclerosis</brief_title>
	<detailed_description>Patients , 8 to18 year age , include proven diagnosis diffuse cutaneous systemic SSc define ACR criterion evidence active inflammatory disease Plus least 1 follow : SSc-related pulmonary disease force vital capacity ( FVC ) hemoglobin-adjusted DLCO &lt; 70 % evidence alveolitis high-resolution CT scan bronchoalveolar lavage . OR : History SSc-related renal crisis disease , active time screen OR : Moderate severe upper and/or lower gastrointestinal involvement AND : Unacceptable toxicity steroid dependence &gt; 0.3 mg/kg/d , OR : Failure respond , unacceptable toxicity MTX &gt; 1mg/kg combination cyclosporine azathioprine cyclophosphamide 2 kg/d Rituximab 375 mg/m2 x 4 dos Imatinib 800 mg/ OR : Disease recurrence taper medication</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>SScrelated pulmonary disease force vital capacity ( FVC ) hemoglobinadjusted DLCO &lt; 70 % evidence alveolitis highresolution CT scan bronchoalveolar lavage History SScrelated renal crisis disease , active time screen Moderate severe upper and/or lower gastrointestinal involvement . Unacceptable toxicity steroid dependence &gt; 0.3 mg/kg/d , Failure respond , unacceptable toxicity MTX &gt; 1mg/kg combination cyclosporine azathioprine cyclophosphamide 2 kg/d Rituximab 375 mg/m2 x 4 dos Imatinib 800 mg/d , Disease recurrence taper medication SSc patient , fulfill modify SCOT criterion , assess residual thymic function since previous study pediatric SSc patient demonstrate SSc patient decrease thymic function compare age match control measure either TREC analysis number naïve CD4+ T lymphocytes ( CD4+ , CD31+ ) . Patients less 50 CD3+ , CD4+ , CD45RA+ , CD31+ cells/ul exclude concern ability reconstitute immune system immune ablation . Organ dysfunction would limit survival less 100 day comorbid illness estimate median life expectancy &lt; 5 year Active uncontrolled infection Endstage lung disease : hemoglobincorrected DLCO &lt; 45 % FVC &lt; 45 % , DLCO &lt; 4 mL/mmHg/min/L pO2 &lt; 70 mm Hg pCO2 , ≥ 45 mm Hg without supplemental O2 sit 92 % rest without supplemental O2 Significant pulmonary hypertension Significant cardiac disease either Uncontrolled clinically significant arrhythmias NYHA heart failure class IV LVEF &lt; 50 % echo prior insertion pacemaker cardioverter defibrillator Uncontrolled hypertension Endstage renal disease ( GFR &lt; 50 ml/min/1.73 m2 creatinine ≥ 2 mg/dl ; estimate CrCl &lt; 40 mL/min active , untreated SSc renal crisis time enrollment . Active hepatitis ( ALT , AST , bilirubin &gt; 2x ULN ) periportal fibrosis liver biopsy Active gastric antral vascular ectasia ( GAVE , `` watermelon stomach '' ) Myelodysplasia Malignancy within previous 2 year , exclude treat skin cancer Positive serology hepatitis B C , HIV ANC &lt; 1500 cells/µL , platelet &lt; 120,000 cells/µL , Hct &lt; 27 % Hgb &lt; 9.0 g/dL History hypersensitivity murine E. coli proteins Pregnancy unwilling use contraceptive method least 15 month Steroid dependence : &gt; 2 mg/kg/day prednisone equivalent within 30 day prior treatment History substance abuse within last 5 year</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Patients Scleroderma</keyword>
</DOC>